Evidence map›Paper›PMID 40352506›Full record

ArticleACS omega2025

Discovery of Novel Allosteric Inhibitor Hits for Insulin-Regulated Aminopeptidase Provides Insights on Enzymatic Mechanism.

Galateia Georgaki, Nikoletta-Maria Koutroumpa, Panagiotis Lagarias, Antreas Afantitis, Athanasios Papakyriakou, Efstratios Stratikos

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Galateia GeorgakiLaboratory of Biochemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou 15784, Greece.
Nikoletta-Maria KoutroumpaNovaMechanics Ltd., Nicosia 1070, Cyprus.
Panagiotis LagariasNovaMechanics Ltd., Nicosia 1070, Cyprus.
Antreas AfantitisNovaMechanics Ltd., Nicosia 1070, Cyprus.ORCID https://orcid.org/0000-0002-0977-8180
Athanasios PapakyriakouNational Centre for Scientific Research Demokritos, Agia Paraskevi 15341, Greece.ORCID https://orcid.org/0000-0003-3931-6232
Efstratios StratikosLaboratory of Biochemistry, Department of Chemistry, National and Kapodistrian University of Athens, Zografou 15784, Greece.ORCID https://orcid.org/0000-0002-3566-2309

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin-regulated aminopeptidase (IRAP) is a transmembrane zinc metalloprotease with various important biological roles, including fibrosis, septic thrombosis, cognitive functions, and immune system regulation. As a result, IRAP is an emerging pharmacological target for several diseases. However, the development of selective inhibitors that specifically regulate its activity remains challenging due to its high sequence and functional homology with many other enzymes that have highly conserved active sites. To circumvent this limitation, we targeted the malate allosteric site, a site that has yielded highly selective inhibitors of the homologous enzyme ERAP1. We performed virtual screening to discover drug-like compounds that bind with high affinity to this allosteric site in IRAP. A database of 38 million diverse, drug-like compounds from ENAMINE was employed for screening at three conformations of the targeted site. A subset of the top-ranked compounds was subsequently evaluated using molecular dynamics simulations and comparative MM/GBSA free energy calculation, from which 17 were selected for further

Identifiers

PMID40352506
PMCPMC12059914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.